Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04338802 |
Recruitment Status : Unknown
Verified April 2020 by Huilan Zhang, Tongji Hospital.
Recruitment status was: Not yet recruiting
First Posted : April 8, 2020
Last Update Posted : April 8, 2020
|
Sponsor:
Huilan Zhang
Information provided by (Responsible Party):
Huilan Zhang, Tongji Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | May 4, 2020 |
Estimated Study Completion Date : | August 1, 2020 |
Publications: